logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Agenus Stock Rallied Yesterday

Why Agenus Stock Rallied Yesterday On September 2, 2020 we posted an article about Agenus ( AGEN ) under Trick or Trade titled, “ Agenus: Could It Be a Resurrection? "   The article was about the data Agenus announced from...

Read More

September 11, 2020

0

Cara Therapeutics and Vifor Pharma Announced the U.S. FDA Approval of KORSUVA™

Cara Therapeutics and Vifor Pharma Granted US FDA Approval of KORSUVA™ Indeed, the U.S. Food and Drug Administration ( FDA ) approved Cara Therapeutics ( CARA ) and  Vifor Pharma injectable product KORSUVA™ (difelikefalin) - a first-in-class kappa opioid receptor (...

Read More

August 24, 2021

0

BioMarin Pharmaceutical Inc Product VOXZOGO® is the First to Prevent Dwarfism in Europe

The most important news in biological sciences is the high degree of success the biological revolution can reach. We can feel the great value every time an untreatable, devastating condition is successfully treated thanks to discoveries made possible through the...

Read More

August 31, 2021

0

Eli Lilly Neutralizing Antibody LY-CoV555 Promises a Reduction in the Rate of COVID-19 Hospitalizations  

Eli Lilly and AbCellera Collaboration Result LY-C0V555  A lot of discoveries, followed by thorough experimentation beyond the vaccines, are taking place in the biotechnology and large biopharmaceutical companies to defeat COVID-19 . The most recently discovered product by AbCellera, which...

Read More

September 16, 2020

0

Celularity Inc NK Cell Therapy CYNK-001 Receives US FDA Fast Track Designation for AML Treatment

Celularity Inc Celularity Inc. ( CELU ) announced the U.S. Food and Drug Administration ( FDA ) has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer ( NK ) cell therapy, CYNK-001...

Read More

December 28, 2021

0

Amgen's KRAS G12C Inhibitor Product Sotorasib Has Thrilling Results

Amgen and the KRAS G12C Protein Discovery The  RAS  gene family has been a subject for four decades of research. The family contains some of the most frequently mutated oncogenes in human cancers. Targeting the KRAS protein, the most commonly...

Read More

September 25, 2020

0

Revolution Medicines Inc Has Revolutionary News

Revolution Medicines Inc Revolution Medicines ( RVMD ) is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers. The company possesses capabilities including deep chemical biology and cancer pharmacology know-how and novel...

Read More

September 25, 2020

0

Gilead Sciences: New Data Demonstrate Trodelvy Survival Benefit in Metastatic TNBC. See Also: Galapagos NV News

Gilead Sciences New Data from Trodelvy® Study Gilead Sciences ( GILD ) has recently announced new data from the Phase 3 ASCENT study evaluating Trodelvy® in patients with relapsed or refractory metastatic triple-negative breast cancer ( TNBC ) who received two...

Read More

September 17, 2021

0

Why Intellia Therapeutics Acquisition of Rewrite Therapeutics Is Important

Intellia Therapeutics Acquires Rewrite Therapeutics The acquisition is, indeed good news. By acquiring Rewrite Therapeutics , Intellia Therapeutics ( NTLA ) has inherited a versatile DNA writing platform which enables a range of innovative genome editing strategies. The acquisition is...

Read More

February 7, 2022

0

Johnson & Johnson Launches a Large Scale Phase 3 Trial of Its COVID-19 Vaccine. See Also: Intellia to Prove the Advantages of CRISPR Gene-Editing

Johnson & Johnson ENSEMBLE Trial for Its COVID-19 Vaccine Candidate Johnson & Johnson ( JNJ ) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial, ENSEMBLE, for its COVID-19 vaccine candidate, JNJ-78436735. The initiation of the ENSEMBLE trial...

Read More

September 29, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 29
  • 30
  • 31
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy